The acquisition by Aurobindo Pharma Limited of a number of Actavis plc operations in seven European countries is not expected to hit the workforce at the two Actavis plants in Malta.
Though Malta was not among the seven countries in the agreement, questions were raised about the company’s future in Malta in the wake of last March’s decision to close the research and development branch in Malta. As a result 64 employees lost their jobs.
Sergio Vella, vice-president manufacturing operations (Western Europe), said Actavis did not expect the agreement to have an impact on its local employment levels in the foreseeable future.
Aurobindo Malta managing director Frederick Schembri said the company was planning to expand its operations in Malta, which served as a testing and batch release site for the company’s European market.